Rainer Tuominen

1.3k total citations
31 papers, 640 citations indexed

About

Rainer Tuominen is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Rainer Tuominen has authored 31 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 22 papers in Oncology and 6 papers in Cell Biology. Recurrent topics in Rainer Tuominen's work include Melanoma and MAPK Pathways (16 papers), Cutaneous Melanoma Detection and Management (16 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Rainer Tuominen is often cited by papers focused on Melanoma and MAPK Pathways (16 papers), Cutaneous Melanoma Detection and Management (16 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Rainer Tuominen collaborates with scholars based in Sweden, United Kingdom and United States. Rainer Tuominen's co-authors include Veronica Höiom, Johan Hansson, Johan Hansson, Hildur Helgadóttir, Håkan Olsson, Suzanne Egyházi Brage, Göran Jönsson, Suzanne Egyházi, Joakim Lundeberg and Marianne Frostvik Stolt and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Scientific Reports and Annals of Oncology.

In The Last Decade

Rainer Tuominen

29 papers receiving 631 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rainer Tuominen Sweden 16 375 339 175 101 79 31 640
Lyndee L. Scurr Australia 17 523 1.4× 235 0.7× 87 0.5× 134 1.3× 108 1.4× 21 765
Natalie E. Simpson United States 14 376 1.0× 169 0.5× 123 0.7× 106 1.0× 31 0.4× 19 649
Helena Joyce Ireland 10 438 1.2× 156 0.5× 172 1.0× 105 1.0× 24 0.3× 12 643
Shinako Araki United States 10 335 0.9× 400 1.2× 166 0.9× 161 1.6× 45 0.6× 14 690
Lorenzo Bombardelli Netherlands 9 375 1.0× 168 0.5× 166 0.9× 73 0.7× 52 0.7× 13 637
Llorenç Coll-Mulet Spain 11 452 1.2× 263 0.8× 93 0.5× 90 0.9× 33 0.4× 12 663
Carla L. Van Den Berg United States 15 586 1.6× 284 0.8× 152 0.9× 65 0.6× 64 0.8× 18 768
Ines Kozar Luxembourg 8 319 0.9× 185 0.5× 112 0.6× 93 0.9× 45 0.6× 9 441
Abhik Mukherjee United Kingdom 17 386 1.0× 309 0.9× 210 1.2× 108 1.1× 46 0.6× 41 776
Aaron P. Jansen United States 8 1.1k 2.8× 236 0.7× 413 2.4× 131 1.3× 85 1.1× 9 1.3k

Countries citing papers authored by Rainer Tuominen

Since Specialization
Citations

This map shows the geographic impact of Rainer Tuominen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rainer Tuominen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rainer Tuominen more than expected).

Fields of papers citing papers by Rainer Tuominen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rainer Tuominen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rainer Tuominen. The network helps show where Rainer Tuominen may publish in the future.

Co-authorship network of co-authors of Rainer Tuominen

This figure shows the co-authorship network connecting the top 25 collaborators of Rainer Tuominen. A scholar is included among the top collaborators of Rainer Tuominen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rainer Tuominen. Rainer Tuominen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Das, Ishani, Rainer Tuominen, Thomas Helleday, et al.. (2021). Coexpression of MTH1 and PMS2 Is Associated with Advanced Disease and Disease Progression after Therapy in Melanoma. Journal of Investigative Dermatology. 142(3). 736–740.e6. 6 indexed citations
2.
Yang, Muyi, Per Johnsson, Lars Bräutigam, et al.. (2021). Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma. Genetics in Medicine. 24(1). 157–169.
3.
Das, Ishani, Helge Gad, Lars Bräutigam, et al.. (2020). AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma. Cell Death and Differentiation. 27(7). 2081–2098. 21 indexed citations
4.
Das, Ishani, Huiqin Chen, Gianluca Maddalo, et al.. (2020). Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma. Cell Death and Disease. 11(10). 882–882. 14 indexed citations
5.
Das, Ishani, Margareta Wilhelm, Veronica Höiom, et al.. (2019). Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status. Cell Death and Disease. 10(9). 663–663. 20 indexed citations
6.
Das, Ishani, Helge Gad, Lars Bräutigam, et al.. (2018). 1180 Effects of MTH1 inhibitor TH1579 on cutaneous melanoma. Journal of Investigative Dermatology. 138(5). S200–S200. 2 indexed citations
7.
Azimi, Alireza, Stefano Caramuta, Brinton Seashore‐Ludlow, et al.. (2018). Targeting CDK 2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors. Molecular Systems Biology. 14(3). e7858–e7858. 55 indexed citations
8.
9.
Helgadóttir, Hildur, Rainer Tuominen, Håkan Olsson, Johan Hansson, & Veronica Höiom. (2017). Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status. Journal of the American Academy of Dermatology. 77(5). 893–901. 29 indexed citations
10.
Azimi, Alireza, Rainer Tuominen, Fernanda Costa Svedman, et al.. (2017). Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells. Cell Death and Disease. 8(8). e3029–e3029. 30 indexed citations
11.
Helgadóttir, Hildur, Veronica Höiom, Rainer Tuominen, et al.. (2016). GermlineCDKN2AMutation Status and Survival in Familial Melanoma Cases. JNCI Journal of the National Cancer Institute. 108(11). djw135–djw135. 47 indexed citations
12.
Tuominen, Rainer, Rosalyn Jewell, Joost J. van den Oord, et al.. (2014). MGMT promoter methylation is associated with temozolomide response and prolonged progression‐free survival in disseminated cutaneous melanoma. International Journal of Cancer. 136(12). 2844–2853. 40 indexed citations
13.
Höiom, Veronica, Daniel Edsgärd, Hildur Helgadóttir, et al.. (2013). Hereditary uveal melanoma: A report of a germline mutation in BAP1. Genes Chromosomes and Cancer. 52(4). 378–384. 40 indexed citations
14.
Lundeberg, Joakim, et al.. (2013). High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma. Melanoma Research. 23(6). 452–460. 23 indexed citations
15.
Höiom, Veronica, Rainer Tuominen, & Johan Hansson. (2011). Genome‐wide linkage analysis of Swedish families to identify putative susceptibility loci for cutaneous malignant melanoma. Genes Chromosomes and Cancer. 50(12). 1076–1084. 7 indexed citations
16.
Johansson, C. Christian, Suzanne Egyházi, Giuseppe Masucci, et al.. (2008). Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunology Immunotherapy. 58(7). 1085–1094. 41 indexed citations
17.
Tuominen, Rainer, et al.. (2006). Amplification of the cyclin D1 locus 11q13 in melanoma metastases: association to cyclin D1 protein expression. Melanoma Research. 16(Supplement 1). S61–S62.
18.
Berg, Peter A., Ann‐Marie Wennberg, Rainer Tuominen, et al.. (2004). Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Research. 14(4). 251–255. 29 indexed citations
19.
Tuominen, Rainer, Margareta Warholm, Lennart Möller, & Agneta Rannug. (2003). Constitutive CYP1B1 mRNA expression in human blood mononuclear cells in relation to gender, genotype, and environmental factors. Environmental Research. 93(2). 138–148. 19 indexed citations
20.
Tuominen, Rainer, Paweł Baranczewski, Margareta Warholm, et al.. (2002). Susceptibility factors and DNA adducts in peripheral blood mononuclear cells of aluminium smelter workers exposed to polycyclic aromatic hydrocarbons. Archives of Toxicology. 76(3). 178–186. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lyndee L. Scurr Breakdown of academic impact, for papers by Natalie E. Simpson Breakdown of academic impact, for papers by Helena Joyce Breakdown of academic impact, for papers by Shinako Araki Breakdown of academic impact, for papers by Lorenzo Bombardelli Breakdown of academic impact, for papers by Llorenç Coll-Mulet Breakdown of academic impact, for papers by Carla L. Van Den Berg Breakdown of academic impact, for papers by Ines Kozar Breakdown of academic impact, for papers by Abhik Mukherjee Breakdown of academic impact, for papers by Aaron P. Jansen
Rankless by CCL
2026